New drug PLB-002 targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-stage study tests a new drug called PLB-002 in about 100 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. PLB-002 is designed to attack cancer cells while sparing heal…
Phase: PHASE1 • Sponsor: Primelink BioTherapeitics(ShenZhen) Limited • Aim: Disease control
Last updated May 16, 2026 06:02 UTC